Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | $0.00 | $0.00 |
| Operating income | -$1.19M | -$16.6M | -$3.33M | -$4.32M | -$6.51M | -$9.13M | -$10.5M | -$8.83M | -$16.2M | -$16.7M |
| Net income | -$1.19M | -$16.6M | -$3.23M | -$4.22M | -$6.30M | -$9.10M | -$10.5M | -$8.40M | -$15.6M | -$13.7M |
| EPS (diluted) | — | -$1.89 | -$0.35 | -$0.45 | -$0.58 | -$0.73 | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.19M | -$2.63M | -$2.68M | -$3.02M | -$4.66M | -$7.32M | -$7.23M | -$7.86M | -$6.40M | -$12.2M |
| Share buybacks | — | — | — | — | — | — | — | — | $0.00 | $35.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.07M | $8.98M | $6.89M | $13.2M | $16.7M | $20.3M | $8.19M | $7.27M | $45.8M | $61.8M |
| Total assets | $2.90M | $9.93M | $7.32M | $13.4M | $16.9M | $20.5M | $13.2M | $7.35M | $60.3M | $141M |
| Total liabilities | $64.5K | $312K | $400K | $724K | $1.18M | $1.58M | $3.14M | $1.76M | $5.25M | $2.89M |
| Shareholders' equity | $2.83M | $9.62M | $6.92M | $12.6M | $15.7M | $18.9M | $10.1M | $5.59M | $55.0M | $138M |
| Retained earnings | -$1.87M | -$18.4M | -$21.7M | -$25.9M | -$32.2M | -$41.3M | -$51.8M | -$60.2M | -$75.8M | -$89.5M |
| Shares (wtd avg diluted) | — | 9.29M | 9.29M | 10.6M | 11.5M | 12.5M | 12.7M | 2.76M | 3.79M | 7.41M |
Every figure is extracted from Monopar Therapeutics’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.